Semaglutide Relieves Heart Failure Symptoms in Patients With Preserved EF and Obesity

Heart failure with preserved ejection fraction — HFpEF — is the condition that has humbled cardiology for two decades. Despite accounting for more than half of all heart failure cases and carrying the same mortality as HFrEF, HFpEF resisted every attempt at pharmacological therapy that succeeded in reduced-EF heart failure: ACE inhibitors, ARBs, beta-blockers, aldosterone antagonists — all were negative in HFpEF. Even SGLT2 inhibitors, which showed benefit, produced smaller effect sizes than in HFrEF. STEP-HFpEF is different: it is the first trial to show a clinically large and unambiguous improvement in HFpEF symptoms by targeting its most common driver — obesity.

The trial enrolled 529 adults with HFpEF (LVEF ≥45%), a BMI of 30 or higher, and elevated NT-proBNP indicating hemodynamic stress — but without type 2 diabetes (a separate STEP-HFpEF DM trial in diabetic HFpEF patients ran concurrently). Participants were randomized to semaglutide 2.4 mg weekly (the cardiovascular dose, same as the SELECT trial[2]) or matching placebo for 52 weeks. The co-primary endpoints were change in KCCQ clinical summary score (KCCQ-CSS — a validated 100-point questionnaire measuring HF-specific quality of life) and change in 6-minute walk distance (6MWD).

The results were unambiguous. KCCQ-CSS improved by 7.8 points more in the semaglutide group than placebo (95% CI 4.8–11.0; p<0.001) — a difference that exceeds the established minimum clinically important threshold of 5 points and approaches the threshold for a "large" treatment effect. 6MWD improved by 20.3 meters more with semaglutide (95% CI 8.6–32.1; p<0.001)[1]. Body weight fell by 13.3% with semaglutide versus 2.6% with placebo — a difference of 10.7 percentage points. CRP fell by 43% more than placebo, NT-proBNP trended lower, and the rate of serious adverse events was lower in the semaglutide group.

Why does a GLP-1 agonist help HFpEF? The mechanistic answer runs through obesity. Obesity raises pericardial fat volume, increases plasma volume, drives inflammation, raises left atrial pressure, and creates a hemodynamic phenotype that looks like HFpEF — elevated filling pressures, exercise intolerance, preserved systolic function. When you reduce that fat and inflammation with semaglutide, the hemodynamic burden on the heart lifts. STEP-HFpEF makes the argument that HFpEF in obese patients is, at least partly, a disease of adiposity — and that treating the adiposity treats the heart failure.

Clinical Context

HFpEF is not one disease but a syndrome with multiple phenotypes — the obese HFpEF patient overlaps substantially with the patient who has metabolic syndrome, atrial fibrillation, hypertension, and often type 2 diabetes. STEP-HFpEF enrolled patients without diabetes, but the companion STEP-HFpEF DM trial[3] showed similar benefits in diabetic HFpEF patients. Together, these trials positioned GLP-1 receptor agonists as the first class to show substantial symptomatic benefit in HFpEF across the glycemic spectrum — though not mortality benefit, which remains elusive.

The practical question is sequencing. Current HFpEF management emphasizes SGLT2 inhibitors (dapagliflozin, empagliflozin), diuretics for congestion, and rigorous comorbidity treatment. The 2024 HF guidelines incorporated GLP-1 RAs as a consideration in obese HFpEF patients based on these data. For the internist or hospitalist managing a patient with HFpEF and obesity who asks whether Ozempic can help their heart failure — the answer from STEP-HFpEF is yes.

Limitations

The trial excluded patients with type 2 diabetes (a separate population studied in STEP-HFpEF DM) and those with EF below 45%, so results may not apply to the full HFpEF spectrum. The 52-week follow-up captures symptom outcomes but does not establish whether semaglutide prevents HF hospitalization or death — the primary hard outcomes trials in HFpEF (SUMMIT[4], others) will address this. Weight loss itself confounds interpretation: it is impossible to separate the cardiac-specific mechanism of semaglutide from the benefit derived purely from adiposity reduction.